Fundraising Fox
Cellergy Bio
Founded 2022 · 16 employees on LinkedIn · 1 known investors
Find your way into Cellergy Bio
Sign up to see every warm intro you have to Cellergy Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cellergy Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cellergy develops allogeneic mitochondrial transplantation therapy, producing GMP-grade purified mitochondria from human primary cells for intravenous, repeated administration. Its therapy targets systemic and degenerative conditions such as CNS disorders, muscle degeneration, and aging, and uses a machine-learning model to predict donor/recipient matching.
Investors · 1
Frequently asked questions
- What does Cellergy Bio do?
- Cellergy develops allogeneic mitochondrial transplantation therapy, producing GMP-grade purified mitochondria from human primary cells for intravenous, repeated administration. Its therapy targets systemic and degenerative conditions such as CNS disorders, muscle degeneration, and aging, and uses a machine-learning model to predict donor/recipient matching.
- Who are Cellergy Bio's investors?
- Cellergy Bio's investors include fresh.fund.